FDA Clinical Hold for Histogen Trial in Knee Regeneration

Histogen was verbally notified about additional questions from FDA for the company’s Investigational New Drug (IND) application package for the planned Phase I/II clinical trial of HST-003. The trial is evaluating the human extracellular matrix (hECM:HST-003) implanted within microfracture interstices and a knee cartilage defect to regenerate...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0